Introduction: Nivolumab has demonstrated efficacy against metastatic NSCLC. Four programmed cell death ligand 1 (PD-L1) immunohistochemistry (IHC) assay systems are available for identification of responders among patients with NSCLC, and these assays show some differing characteristics. Accordingly, in this study, we evaluated the ability of these assays to identify responders to nivolumab therapy.
Introduction
Recently, programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors have demonstrated efficacy in patients with advanced NSCLC. Nivolumab (Bristol-Myers Squibb, Lawrenceville, NJ) is approved as a treatment choice for previously treated NSCLC after accumulation of data from the CheckMate-017 and CheckMate-057 clinical studies. 1, 2 Subsequently, pembrolizumab (Merck Sharp and Dohme, Kenilworth, NJ), atezolizumab (Genentech/Roche, South San Francisco, CA), and durvalumab (AstraZeneca, Wilmington, DE) have been developed as PD-1/PD-L1 inhibitors. [3] [4] [5] [6] [7] The identification of patient selection markers for PD-1/PD-L1 inhibitors is critical because of the high treatment costs and potential toxicities associated with these inhibitors. Evidence from clinical trials has revealed that PD-L1 expression on tumor cells (TCs), as assessed by immunohistochemistry (IHC), is a biomarker for predicting the treatment efficacy of immunotherapy. 8, 9 However, the current "one drug-one diagnostic test codevelopment approach" for the approval of therapeutic products has resulted in the production of individual PD-L1 diagnostic systems for each PD-1/PD-L1 inhibitor. Each IHC assay system requires a unique primary antibody against PD-L1, namely, 28-8 (nivolumab), 22C3 (pembrolizumab), SP142 (atezolizumab), and SP263 (durvalumab), with specific staining platforms, IHC protocols, scoring algorithms, and cutoffs. In addition to measurement of TCs, measurement of infiltrating PD-L1-positive immune cells (ICs) is also required in the scoring of SP142 assays. 6, 7 The presence of multiple PD-L1 IHC assay systems has also resulted in several clinical problems. 10 The biggest problem is the potential interchangeability of U.S. Food and Drug Administration-approved PD-L1 assay systems (i.e., whether these assays identify responders to PD-1 axis inhibitors equivalently). Indeed, there is substantial interest in the interchangeability of PD-L1 assay systems because of the limited availability of tumor tissue, cost of diagnostic assays, depletion of staining platforms, and complexity of interpretation with multiple tests. 11, 12 Previous studies have shown that scoring of PD-L1 expression on TCs is concordant but somewhat different among these assays. 13 Specifically, 3% to 19% of specimens with a PD-L1 tumor proportion score (TPS) of 50% or higher by one PD-L1 assay were reported as being classified as discordant (<50%) in another PD-L1 assay. [14] [15] [16] However, these studies lack outcome data, as patients were not treated with PD-1 axis therapies. Therefore, clinical concordance studies are needed to demonstrate the ability of these assays to identify the responders in patients treated with PD-1 axis therapies. 16 Thus, in this study, we aimed to use clinical data to compare the predictive performance of the four PD-L1 IHC assay systems and to consider the possibility of interchangeability of these assays.
Materials and Methods

Patients and Tumor Specimens
We retrospectively analyzed patients with previously treated advanced NSCLC, who were administered nivolumab at Kobe City Medical Center General Hospital between April 2016 and September 2016 (Fig. 1) . We included patients for whom we had evaluable specimens. Samples were considered adequate for interpretation if 100 or more TCs were present on hematoxylin and eosin-stained sections. Patients who reported never having smoked were classified as never-smokers, those who had smoked within 1 year of the diagnosis were categorized as current smokers, and the remaining patients were considered former smokers. All patients were classified on the basis of their clinical stage according to the seventh edition TNM classification. 17 Progression-free survival (PFS) was defined as the period from the day of commencement of nivolumab until progression of lung cancer or death from any cause or the end of the follow-up. Data cutoff was conducted on January 31, 2017. The patients had been selected for another prospective observational trial (UMIN000022037). Thus, all patients received computed tomography scans within 30 days before commencing nivolumab treatment. Clinical tumor assessment was performed using the Response Evaluation Criteria in Solid Tumors, version 1.1. 18 A computed tomography scan was performed every 8 to 12 weeks to assess tumor response. We isolated tumor DNA from various specimens and analyzed the mutational status of the EGFR gene at exons 18 to 21 by using the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method, as described previously. 19 Anaplastic lymphoma kinase gene (ALK) translocation was assessed by IHC or fluorescence in situ hybridization break-apart probes, as described previously. 20 This study was approved by the Kobe City Medical Center General Hospital Ethics Committee (zn161106). All tumor specimens in the pathological analysis were obtained after informed consent had been secured from the patients and with approval by our Ethics Committee. Informed consent for the use of clinical information was waived because of the retrospective study design.
Tissue Processing and IHC
PD-L1 expression in NSCLC specimens was analyzed with IHC staining by using the four assay systems (28-8, 22C3, SP142, and SP263). Four-micron-thick sections were cut serially from formalin-fixed, paraffin-embedded tumor blocks and then routinely deparaffinized and rehydrated. Cut sections were stained within 10 days.
For the 28-8 and 22C3 assays, sections were stained with anti-PD-L1 28-8 rabbit monoclonal primary antibodies or anti-PD-L1 22C3 mouse monoclonal primary antibodies by using the EnVision FLEX visualization system on a Dako Autostainer Link 48 system, as described in the PD-L1 IHC 28-8 and 22C3 pharmDx package inserts (Agilent Technologies, Santa Clara, CA). 21, 22 For the SP142 assay, sections were stained with anti-PD-L1 (SP142) rabbit monoclonal primary antibodies and a matched rabbit immunoglobulin G-negative control with an OptiView DAB IHC Detection Kit, followed by an OptiView Amplification Kit on the BenchMark XT automated staining platform (Ventana Medical Systems, Tucson, AZ). 6 Sections were also stained with anti-PD-L1 (SP263) rabbit monoclonal primary antibodies and a matched rabbit immunoglobulin G-negative control with an OptiView DAB IHC Detection Kit on a BenchMark XT automated staining platform. 23 
IHC Evaluation
Samples were anonymized, and four pathologists from two institutions independently scored all 160 immunostained slides from the 40 cases according to the respective scoring algorithms for these assays. TCs were considered PD-L1-positive, if the cell membrane was partially or completely stained. Cytoplasmic PD-L1 staining in TCs was disregarded, and the staining intensity was not considered. Hematoxylin and eosin staining was used for each case to help orientate the pathologists' reading of the IHC slides. TPSs of PD-L1 in TCs were expressed as the percentage of PD-L1-positive TCs in the overall tumor sections and estimated in increments of 5% except for 1% positivity of TCs. The pathologists were blinded to the clinical data; they did not discuss any of the staining interpretations beforehand and did not confer during the scoring process. In cases of disagreement, the slides were reexamined until a consensus was reached through central review with a senior observer (J. F.).
PD-L1 IHC Cutoffs of TCs by the 28-8, 22C3, SP142 and SP263 Assays
Several cutoffs for PD-L1 expression have been used in clinical trials. We set 1% and 50% as cutoff values. This is the validated cutoff value of the 22C3 assay system, which is the official companion diagnostic of pembrolizumab. 5 Additionally, the definition of TC3 in the SP142 assay system is also a TPS of 50% or higher. 7 Moreover, in the recent CheckMate 026 study (nivolumab), efficacy data for a TPS of 50% or higher were presented. 24 Accordingly, we concluded that 1% and 50% were reasonable cutoff values for this comprehensive comparison. Each sample was classified as negative (TPS <1%), weakly positive (TPS 1%-49%), or strongly positive (TPS !50%).
PD-L1 Evaluation and Cutoffs of ICs by the SP142 Assay
As an additional analysis, the TC/IC scoring system assessed by SP142 assays was also evaluated. 6, 7 For SP142, IC staining (an estimate of the percentage of ICs, including macrophages and lymphocytes within the tumor exhibiting membrane or cytoplasmic staining) was assessed. The scoring was based on the previously established scoring guideline. 25 ICs were identified by morphologic features only, without the use of other IC biomarkers. We set 1%, 5%, and 10% as cutoff values, according to the previous clinical trials. 6, 7 Repeated Analysis of PD-L1 IHC in Discordant Cases with the 50% Cutoff
We repeated PD-L1 IHC analysis of discordant cases with the 50% cutoff by four assays. We defined the term discordant cases with the 50% cutoff as those classified as strongly positive in one assay but not in another assay. PD-L1 TPS were also determined by four pathologists. In cases of disagreement, the slides were reexamined until a consensus was reached.
Statistical Analysis
Continuous variables were analyzed by Student's t tests. Dichotomous variables were analyzed with Fisher's exact tests. The Kaplan-Meier method was used to estimate PFS, and groups were compared by using the logrank test. The concordance between the PD-L1 IHC assay systems was determined with weighted k index 
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Predictive Performance of Four PD-Ll Assays(weight 0, 1, or 3) with 95% confidence intervals. The predictive performance for predicting response to nivolumab was determined by receiver operating characteristic (ROC) analysis. 26 A test with an area under curve (AUC) of 0.9 or higher was considered to have high accuracy, that with an AUC of 0.7 to 0.9 was considered to have moderate accuracy, and that with an AUC of 0.5 to 0.7 was considered to have low accuracy. A two-tailed p value less than 0.05 indicated statistical significance. We conducted statistical analyses using JMP 11 software (SAS Institute Inc., Cary, NC) and R statistical software, version 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Patient Characteristics
In total, 40 patients with advanced NSCLC were included in this study. Patient characteristics are summarized in Table 1 . All patients had stage IIIb or IV NSCLC. Their mean age was 67.8 years, 28 patients (70%) had the adenocarcinoma histologic type, the tumors of 30 patients (75%) were diagnosed by small biopsy, 36 specimens (90%) were archived, and the interval from biopsy to nivolumab administration was 11.5 months (interquartile range 5.4-31.8). The overall rate of response to nivolumab was 25%, and the median PFS was 2.6 months. EGFR mutation and ALK translocation were tested in 34 patients. Among those patients, seven showed mutated EGFR or were ALK positive. The remaining six patients had squamous cell histologic type, and these were not investigated.
PD-L1 Staining of TCs and Comparisons by 1% and 50% Cutoffs
All PD-L1 staining was successfully conducted by using four PD-L1 assays: 28-8, 22C3, SP142, and SP263. Representative images of the IHC are shown in Supplementary Figure 1 . The distributions of percentages of TC staining for each assay, as agreed on by four pathologists, are shown in Supplementary Figure 2 and Supplementary Table 1. Overall, these assays showed relative staining equivalency. Among them, SP142 consistently showed fewer TCs expressing PD-L1, and 22C3 and SP263 showed slightly more than those shown by 28-8. However, the three assays 28-8, 22C3, and SP263 had almost similar distributions across cases.
Next, the distributions of TPS stratified by the two cutoffs (1% and 50%) were analyzed. Different frequencies of PD-L1 intensities were observed among the assays. Specifically, the results of the 28-8, 22C3, SP263, and SP142 assays were negative (TPS <1%) for 48%, 55%, 45%, and 73% of patients, respectively; weakly positive (TPS 1%-49%) for 38%, 25%, 40%, and 23%, respectively; and strongly positive (TPS !50%) for 15%, 20%, 15%, and 5%, respectively.
To quantify potential concordance and differences among the four assays in PD-L1 classifications, six pairwise comparisons of the four assays were generated ( Table 2 ). The 28-8, 22C3, and SP263 assays showed higher concordance (weighted k coefficient: 0.64-0.71), whereas comparisons between SP142 and other assays showed lower concordance (weighted 1% [B] ). The overall agreement rates were 83% and 55%, respectively. TPS, tumor proportion score.
Comparison of Predictive Performance Classified by the Four Assays
Respective TPS results and clinical efficacy are summarized in Supplemental Table 1 . The relationships among PD-L1 TPSs and response rates (RRs), disease control rates (DCRs), and PFS times are summarized in Table 3 . Patients who were strongly positive for PD-L1 stratified by each of the four assays (28-8, 22C3, SP263, and SP142) had excellent RRs (100%, 75%, 83%, and 100%, respectively), DCRs (100%, 88%, 83%, and 100%, respectively), and PFS times (not yet reached), whereas patients who were weakly positive had worse RRs (7%, 20%, 19%, and 33%, respectively), DCRs (40%, 50%, 50%, and 56%, respectively), and PFS times (1.6, 2.6, 2.6, and 2.6 months, respectively). Patients who were negative also had worse RRs (16%, 9%, 11%, and 17%, respectively), DCRs (42%, 36%, 39%, and 45%, respectively), and PFS times (2.1, 2.0, 2.1, and 2.1 months, respectively). The Kaplan-Meier curves for each assay are shown in Figure 3 . The PFS times of patients who were strongly positive for PD-L1, as stratified by the 28-8, 22C3, and SP263 assay systems, were significantly longer than those of patients who were negative for PD-L1, whereas that of patients who were strongly positive for PD-L1 as stratified by SP142 was longer without a significant difference. The PFS times of patients who were strongly positive, as classified by the four assays, are shown as Kaplan-Meier curves in Supplementary Figure 4A . Those of patients who were weakly positive or negative are also shown in Supplementary Figure 4B and C. For each assay system, we conducted ROC analysis to predict responses to nivolumab to compare the predictive performance of each assay system (Table 3) . The assays 28-8, 22C3, and SP263 showed moderate accuracy (AUC 0.75-0.82), whereas SP142 showed lower accuracy (AUC 0.68).
PD-L1 Staining of ICs and Its Association with Treatment Efficacy
The distributions of PD-L1 expression on ICs as assessed by SP142 assays and related treatment efficacy are shown in Supplementary Table 2. The RRs of IC0, IC1, IC2, and IC3 were 17%, 0%, 43%, and 100%, respectively. ICs assessed by SP142 assays showed lower accuracy for response to nivolumab (AUC 0.55). The Kaplan-Meier curves of PD-L1 IC proportions (IC0-IC3) are shown in Supplementary Figure 5 .
The results of TC and IC combination assessments of SP142 are presented in Supplementary Table 2. 6,7 The Kaplan-Meier curves of TC and IC combination assessment are shown in Supplementary Figure 6 . According to clinical trials, we stratified three groups: TC0 and IC0 (negative), TC3 or IC3 (strongly positive), and others (weakly positive). We then compared the predictive performance between TC only and TC and IC combination assessment. The RRs of patients who were strongly positive were 100% versus 60% (TC only versus TC/IC combination assessment, respectively); those of patients who were weakly positive were 33% versus 33%, respectively; and those of patients who were negative were 15% versus 17%, respectively. Therefore, the predictive performance of the SP142 assay system did not improve by adding the IC assessment.
Treatment Outcome of Discordant Cases with the 50% Cutoff by the Three Assays (28-8, 22C3, and SP263)
Among the 28-8, 22C3, and SP263 assays, there were four discordant cases with the 50% cutoff (two patients with strongly positive 22C3 results and weakly positive 28-8 and SP263 results, one patient with strongly positive 28-8 and 22C3 results and weakly positive SP263 results, and one patient with strongly positive SP263 results and weakly positive 28-8 and 22C3 results). The RR of discordant cases with the 50% cutoff was 25% (n ¼ 4), whereas that of patients classified as strongly positive by all three assays was 100% (n ¼ 5); however, these data are inconclusive because of the small number of patients.
Repeated Analysis of PD-L1 IHC in Discordant Cases with the 50% Cutoff
There were seven discordant cases with the 50% cutoff in our study. One patient was excluded from this analysis because of insufficient specimen. In total, we repeated PD-L1 IHC for six discordant cases with the 50% cutoff. The results are shown in Supplementary  Table 3 . In repeated IHC analysis, patients with strongly positive 28-8, 22C3, and SP263 results and weakly positive SP142 results (cases 36 and 39) showed discordant results with the 50% cutoff. However, four patients (cases 26, 30, 32, and 35) were classified as concordant cases for all assays with the 50% cutoff. In particular, repeated analysis showed that five specimens were classified differently (SP263 of case 26, 22C3 of case 30, 22C3 of case 32, and 28-8 and 22C3 of case 35).
In these cases, we found clear differences in TPS between the first and second IHC results. The representative PD-L1 IHC results are shown in Supplementary  Figure 3 .
Discussion
To the best of our knowledge, this study provides the first comparison of the predictive performances of four PD-L1 IHC assay systems in patients with advanced NSCLC who received nivolumab therapy. We found that 28-8, 22C3, and SP263 had equivalent predictive performance, whereas SP142 had lower predictive performance.
Our results showed that staining was similar for the 28-8, 22C3, and SP263 assay systems, whereas SP142 showed different staining. In our study, three of the assays (28-8, 22C3 , and SP263) were statistically similar in analytical performance with good concordance (weighted k coefficient 0.64-0.71), whereas the SP142 assay generally stained fewer TCs and showed a low concordance rate (weighted k coefficient 0.39-0.55). Moreover, the agreement rate with the 50% cutoff among 28-8, 22C3, and SP263 was significantly high (90%). The distributions of patients who were strongly positive, weakly positive, and negative for PD-L1, as assessed by the 28-8, 22C3, SP263, and SP142 assays, were similar to the data reported in a recent study. 16 Additionally, similar results were reported in three previous harmonization studies. 13, 14, 16 Considering these findings and our present data, the staining results of the 28-8, 22C3, and SP263 assays were concordant, whereas the assay SP142 was an outlier.
We clearly demonstrated equivalent predictive performance in the 28-8, 22C3, and SP263 assays for nivolumab treatment. The overall RRs and PFS times of patients who tested strongly positive for PD-L1, as classified by these four assays, were considerably better than those of patients who tested weakly positive or negative. These results were consistent with those of previously reported trials. [1] [2] [3] [4] [5] 8 ROC analysis showed that three of the assays (28-8, 22C3, and SP263) had equivalent predictive performance in response to nivolumab (AUC 0.75-0.82), whereas SP142 had lower predictive performance (AUC 0.68). 26 In the KEYNOTE 001 biomarker cutpoint study, the 22C3 assay system exhibited an AUC of 0.74 as a predictive biomarker for the pembrolizumab response. 27 Therefore, the 28-8 and SP263 assays exhibited similar predictive performance, as shown in the 22C3 assay system in our study.
We also assessed PD-L1 expression on ICs and predictive performance by SP142 assays. However, we found lower predictive performance of ICs than that of TCs. Furthermore, the TC and IC combination assessment algorithm led to worse predictive performance. Previous studies reported that IC scoring is difficult. 13, 28 Another study also reported extremely high intraobserver differences in IC scoring. 16 Therefore, IC measurement by SP142 assays may not improve predictive performance in the assessment of clinical efficacy of nivolumab. Oncologists should acknowledge the differing characteristics of SP142, and they may consider replacing SP142 with other assays systems. Further large-scale study is needed to confirm these results.
As reported previously, some patients showed discordant IHC status by the different PD-L1 assays in our study.
14-16 Therefore, we conducted repeated IHC analysis of discordant cases with the 50% cutoff. Patients with strongly positive 28-8, 22C3, and SP263 results and weakly positive SP142 results were classified as discordant again. However, the remaining four patients were classified as concordant cases on the basis of weakly positive results of all assays. Surprisingly, we found clear differences of TPS between first and second IHC results in these cases. The precise reason for this discrepancy between the first and second IHC results is unclear. There are various possible explanations such as tumor heterogeneity, variability in the age of cut slides between the first and second replicate, and variability in the performance of the staining platform. Particularly, three specimens tested by the 22C3 assay showed discordant first and second IHC results; the proportion is higher among four assays. High variability between replicates tested by the 22C3 assay can cause clinical problems, because the 22C3 assay is a U.S. Food and Drug Administration-approved companion diagnostic assay. However, the number of discordant cases in this study is small and further studies involving a larger number of cases are essential to investigate the reason for and more precise frequency of discordance between the first and second replicate.
The main purpose of the present study was to analyze the possibility of interchanging the four PD-L1 assay systems using clinical data. As reported previously, some patients were misclassified by the different PD-L1 assays in our study. [13] [14] [15] [16] However, minimal differences were observed in predictive performance of the 28-8, 22C3, and SP263 assays. This is because discordant cases with the 50% cutoff were found randomly among the three assays. Moreover, the response of discordant cases with the 50% cutoff was not high. Thus, discordant cases influenced the predictive performance of each assay minimally. From our data, we believe that the interchangeability of three assays (28-8, 22C3 , and SP263) is clinically possible. Further research using clinical data is warranted.
Our study had some limitations. First, this was a retrospective, single-center study with a small number of Japanese patients. Thus, though the result of this study is clinically important, it does not lead to a firm conclusion. Second, patients were treated only with nivolumab in our study. During the study period, PD-1 axis inhibitors other than nivolumab were not approved in Japan. Clinical data on the efficacy of PD-1/PD-L1 inhibitors other than nivolumab are also needed.
In conclusion, our study revealed that the 28-8, 22C3, and SP263 PD-L1 IHC assays were equivalent with regard to predictive evaluation of nivolumab, whereas SP142 had lower predictive performance. Interchangeability of the 28-8, 22C3, and SP263 assay systems may be possible on the basis of analytical and predictive performance. We hope that future clinical concordance data will help to overcome the clinical problems associated with multiple PD-L1 IHC assay systems.
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